If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02508064","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"Part 1","arm_group_description":"BMS-663068 1 × 600 mg extended-release (ER) tablet formulation","arm_type":"Experimental"},{"arm_group_label":"Part 1: Prototype 1","arm_group_description":"BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)","arm_type":"Experimental"},{"arm_group_label":"Part 1: Prototype 2","arm_group_description":"BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)","arm_type":"Experimental"},{"arm_group_label":"Part 1: Prototype 3","arm_group_description":"BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)","arm_type":"Experimental"},{"arm_group_label":"Part 1: Prototype 4","arm_group_description":"BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)","arm_type":"Experimental"},{"arm_group_label":"Part 1: Prototype 5","arm_group_description":"BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)","arm_type":"Experimental"},{"arm_group_label":"Part 2","arm_group_description":"BMS-663068 1 × 600 mg ER tablet formulation","arm_type":"Experimental"},{"arm_group_label":"Part 2: Prototype 1","arm_group_description":"BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)","arm_type":"Experimental"},{"arm_group_label":"Part 2: Prototype 2","arm_group_description":"BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)","arm_type":"Experimental"},{"arm_group_label":"Part 2: Prototype 3","arm_group_description":"BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)","arm_type":"Experimental"},{"arm_group_label":"Part 2: Prototype 4","arm_group_description":"BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)","arm_type":"Experimental"}],"assignment":"Crossover Assignment","brief_summary":"This 2-part study will determine the bioavailability of BMS-626529 in healthy subjects from prototype low dose extended release formulations (Part 1) of BMS-663068 and prototype extended release multi-particulate formulations (Part 2) of BMS-663068 relative to 600 mg extended release tablet of BMS-663068.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Bioavailability of BMS-626529 in healthy subjects from prototype low dose extended release formulations (Part 1) and prototype extended release multi-particulate formulations (Part 2) of BMS-663068 relative to 600 mg extended release tablet","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:35:08","criteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Males and females, 18 to 50 years of age, inclusive - Healthy subjects as determined by no clinically significant deviation from normal in medical and surgical history, PE findings, vital sign measurements, 12-lead ECG measurements, physical measurements, and clinical laboratory test results - Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (performed for all females; minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study drug Exclusion Criteria: - Any significant acute or chronic medical illness - Evidence of organ dysfunction or any clinically significant deviation from normal in PE, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population - Any of the following on 12-lead ECG prior to study drug administration, confirmed by repeat: i) PR ≥ 210 msec ii) QRS ≥ 120 msec iii) QT ≥ 500 msec and iv) QTcF ≥ 450 msec - Exposure to any investigational drug or placebo within 12 weeks of study drug administration - Positive blood screen for hepatitis C antibody (HCV Ab), hepatitis B surface antigen (HBsAg), or HIV-1 and HIV-2 antibody","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"27","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"6272bbc7-8833-5d56-939c-9dee2855389f","internal":{"content":null,"contentDigest":"2c7a87b12a6b1ddbe2ebcd1cdf300219","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Males and females, 18 to 50 years of age, inclusive - Healthy subjects as determined by no clinically significant deviation from normal in medical and surgical history, PE findings, vital sign measurements, 12-lead ECG measurements, physical measurements, and clinical laboratory test results - Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (performed for all females; minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study drug Exclusion Criteria: - Any significant acute or chronic medical illness - Evidence of organ dysfunction or any clinically significant deviation from normal in PE, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population - Any of the following on 12-lead ECG prior to study drug administration, confirmed by repeat: i) PR ≥ 210 msec ii) QRS ≥ 120 msec iii) QT ≥ 500 msec and iv) QTcF ≥ 450 msec - Exposure to any investigational drug or placebo within 12 weeks of study drug administration - Positive blood screen for hepatitis C antibody (HCV Ab), hepatitis B surface antigen (HBsAg), or HIV-1 and HIV-2 antibody","interventions":[{"arm_group_label":"Part 2: Prototype 2","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 1: Prototype 2","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 1","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 1: Prototype 5","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 1: Prototype 4","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 2","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 2: Prototype 1","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 1: Prototype 3","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 2: Prototype 4","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 1: Prototype 1","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"Part 2: Prototype 3","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"}],"interventional_subtype":"Health Services Research","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":[],"last_follow_up_date":"11/05/2015 00:00:00","links":[],"locations":[{"City":"Nottingham","Latitude":"52.881347","CountryDisplay":"United Kingdom","Longitude":"-1.1472342","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"NG11 6JS","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"50 years","maximum_age":"50","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:45:13","number_of_arms":"11","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Two-Part Study to Evaluate the Bioavailability of BMS-626529 Administered as Prodrug BMS-663068 from Prototype Low-Dose Extended-Release Tablets (Part 1) and Prototype Multi-Particulate Formulations (Part 2) Relative to the 600 mg Extended Release Tablet in Healthy Subjects","org_study_id":"206288","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"11/05/2015 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Maximum observed concentration (Cmax) of BMS-626529","outcome_time_frame":"Day 1 to Day 4 of each period","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of BMS-626529","outcome_time_frame":"Day 1 to Day 4 of each period","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-626529","outcome_time_frame":"Day 1 to Day 4 of each period","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI438-054","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Safety of BMS-663068 will be measured by incidence of Adverse events (AEs), Serious adverse events (SAEs), and AEs leading to discontinuation;, and results of clinical laboratory tests, vital signs, 12-lead ECGs, and Physical examination (PE)","outcome_time_frame":"Day 1 to Day 4 of each period; for SAEs up to 30 days post discontinuation of dosing","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Tolerability of BMS-663068 will be measured by incidence of AEs, SAEs, and AEs leading to discontinuation; and results of clinical laboratory tests, vital signs and 12-lead ECGs","outcome_time_frame":"Day 1 to Day 4 of each period; for SAEs up to 30 days post discontinuation of dosing","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"08/03/2015 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206288"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}